Cancer Care Advancing with New Therapies

Cancer research has undergone significant transformation in recent years. Advancements in precision oncology, immunotherapies, cell and gene therapies, alongside molecular diagnostics and digital networking, have dramatically accelerated progress. At the Hauptstadtkongress Medizin und Gesundheit in Berlin, experts debated how to ensure that more people can benefit from "new level oncology," representing the next stage in cancer fighting.

Germany records approximately 600,000 new cancer diagnoses annually, with around 250,000 deaths. While cancer is the second leading cause of death, the overall five-year survival rate stands at 67 percent. Projections indicate a 20 percent increase in cancer cases between 2020 and 2040. The field of oncological drug research is experiencing a boom, with 66 percent of new drugs approved in the US since 2000 being cancer-related.

The latest generation of cancer medications offers greater precision, efficacy, and fewer side effects. Professor Lena Illert from the University Hospital Göttingen highlighted that "new level oncology," particularly immune and targeted therapies, is reshaping treatment paradigms. Chemotherapies now constitute only about ten percent of new oncological drug approvals.

Immunotherapies aim to harness the body's immune system to combat cancer cells. T-cells are crucial, and their effectiveness is enhanced by various antibodies, with over 70 currently available for tumor patients. For instance, PD-1 inhibitors help the immune system identify cancer cells by removing their camouflage. Illert noted a significant increase in such antibodies, from one in 2011 to 15 in 2025, approved for more than twenty cancer types.

However, optimization remains key. Research suggests that the timing of immune checkpoint blockade therapy (before or after 3 PM) may influence treatment success, possibly due to T-cells being more "active" in the morning. mRNA vaccines have also shown potential in improving T-cell function and enhancing antibody therapy outcomes. Researchers emphasize the dramatically increasing global demand for modern cancer medicine, coupled with rapid advancements in diagnostics.